Merit Medical CEO Exercises Options; 124,824 Shares Surrendered for Taxes
Rhea-AI Filing Summary
Merit Medical Systems insider transactions: The company's President and CEO, Fred P. Lampropoulos, reported multiple stock option exercises and share surrenders on 08/29/2025. He exercised 159,151 options at a $55.73 exercise price and an additional 2,000 options at $55.73, resulting in 159,151 and 2,000 underlying shares respectively that were reported as acquired. He also surrendered 124,824 shares (for payroll taxes and option payment) and his spouse surrendered 1,454 shares for the same purpose; neither surrender involved open-market sales. Post-transactions, Mr. Lampropoulos beneficially owned 1,204,779 shares directly and certain additional shares indirectly through spouse and 401(k) holdings. Several outstanding option grants with various exercise prices and vesting schedules remain.
Positive
- Large exercise of 159,151 options at $55.73 demonstrates use of equity compensation rather than cashless market sales
- No open-market sales for surrendered shares; surrenders were to the issuer for payroll taxes and option payment
Negative
- Material share surrender of 124,824 shares by the reporting person reduces his direct share count
- Potential dilution remains from multiple outstanding option tranches with various exercise prices and future vesting
Insights
TL;DR: CEO exercised sizable options and surrendered shares for tax/option costs; disclosures are routine but notable for scale.
The reported exercises of 159,151 and 2,000 options at $55.73 and the surrender of 124,824 shares for payroll taxes/option payment are standard executive equity activities that reduce option overhang and increase exercised-share count. The spouse holdings are disclosed and expressly disclaimed by the reporting person. Vesting schedules for multiple option tranches remain in place, indicating continued potential future equity dilution as options vest.
TL;DR: Large option exercises change share composition but represent internal compensation mechanics, not open-market disposition.
The exercises at $55.73 and the share surrenders were not open-market sales, per the filing. Post-transaction direct beneficial ownership is 1,204,779 shares, with additional indirect holdings via spouse and a 401(k). Multiple option grants with exercise prices of $37.71, $56.25, $70.58 and vesting schedules remain outstanding, which may affect future dilution and executive incentive alignment.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-qualified stock options (right to buy) | 159,151 | $0.00 | -- |
| Exercise | Non-qualified stock options (right to buy) | 2,000 | $0.00 | -- |
| Exercise | Common Stock, No Par Value | 159,151 | $55.73 | $8.87M |
| Tax Withholding | Common Stock, No Par Value | 124,824 | $90.54 | $11.30M |
| Exercise | Common Stock, No Par Value | 2,000 | $55.73 | $111K |
| Tax Withholding | Common Stock, No Par Value | 1,454 | $90.54 | $132K |
| holding | Non-qualified stock options (right to buy) | -- | -- | -- |
| holding | Non-qualified stock options (right to buy) | -- | -- | -- |
| holding | Non-qualified stock options (right to buy) | -- | -- | -- |
| holding | Common Stock, No Par Value | -- | -- | -- |
| holding | Common Stock, No Par Value | -- | -- | -- |
Footnotes (1)
- The 401(k) number represents plan holdings as of 08/29/2025. Represents securities held by the spouse of the Reporting Person. The Reporting Person expressly disclaims beneficial ownership of the securities owned by his spouse. The Reporting Person surrendered 124,824 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market. The Reporting Person's spouse surrendered 1,454 shares of common stock to the Issuer for payroll taxes and payment of the option price. No shares were sold in the open market. Becomes exercisable in equal annual installments of 20% commencing 3/1/2020. Original grant of 10,000 options was to become vested and exercisable in equal annual installments of 20% commencing 3/1/2020. Options not vested as of 6/22/2020 have been forfeited. Becomes exercisable in equal annual installments of 25% commencing 2/26/2021. Becomes exercisable in equal annual installments of 25% commencing 3/19/2022. Becomes exercisable in equal annual installments of 25% commencing 2/28/2024.
